help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimering, M. B.
Right arrow Articles by Friesen, H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimering, M. B.
Right arrow Articles by Friesen, H. G.

Journal of Clinical Endocrinology & Metabolism, Vol 79, 1546-1552, Copyright © 1994 by Endocrine Society

ARTICLES

Circulating fibroblast growth factor-like autoantibodies in two patients with multiple endocrine neoplasia type 1 and prolactinoma

MB Zimering, DJ Riley, S Thakker-Varia, AM Walker, V Lakshminaryan, R Shah, ML Brandi, S Ezzat, N Katsumata and HG Friesen
Veterans Affairs Medical Center, Lyons, New Jersey 07939.

Basic fibroblast growth factor (bFGF) is a potent endothelial cell mitogen found in a variety of normal and tumor tissues. bFGF lacks a classical amino-terminal signal sequence and is not readily detectable in plasma from normal subjects. In earlier studies we showed increased bFGF-like mitogenic activity for parathyroid-derived endothelial cells and (increased) bFGF immunoreactivity (0.24-1.28 ng/mL) in plasma of subjects with multiple endocrine neoplasia type 1 (MEN-1). In the present study we examined the proliferative activity of MEN-1 and normal plasmas (applied to protein-A columns) in calf pulmonary artery endothelial cells. Protein-A-eluted activity in plasma from MEN-1 prolactinoma plasma exceeded activity from normal and MEN-1 nonprolactinoma plasma in three of eight MEN-1 subjects with untreated or recurrent prolactinoma. Protein-A-eluted active fractions from MEN-1 prolactinoma plasma had several properties of an immunoglobulin G, including affinity for antihuman immunoglobulin G (IgG) agarose, sensitivity to thiols, and (prepared by sodium dodecyl sulfate- polyacrylamide gel electrophoresis under reducing conditions) apparent mol wt corresponding to those of the heavy and light chains of IgG. The IgG fraction of MEN-1 prolactinoma plasma had far more activity in endothelial cells than did optimal concentrations of known growth factors or conditioned medium from prolactinoma cells. Endothelial cell bioactivity in protein-A-eluted fractions from MEN-1 prolactinoma plasma was neutralized 70% by rabbit antibodies to intact bFGF. These results imply novel growth stimulatory bFGF-like autoantibodies in a subset of MEN-1 patients with prolactinoma.


This article has been cited by other articles:


Home page
 LupusHome page
I Krause, Z Blumenfeld, M Malchinsky, S Cohen, M Blank, A Eldor, B Weksler, K Schweitzer, and Y Shoenfeld
Anti-endothelial cell antibodies in the sera of hyperprolactinemic women
Lupus, July 1, 1998; 7(6): 377 - 382.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. Shimon and S. Melmed
Pituitary Tumor Pathogenesis
J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1675 - 1681.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
D. Ray and S. Melmed
Pituitary Cytokine and Growth Factor Expression and Action
Endocr. Rev., April 1, 1997; 18(2): 206 - 228.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society